[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604587":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":29,"responsibleParty":49,"collaborators":11,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":11,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":11,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":11,"overallStatus":71,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"First Affiliated Hospital of Wenzhou Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"conventional course prednisolone arm","ACTIVE_COMPARATOR",null,[13],"Drug: Conventional 24-week glucocorticoid regimen",{"label":15,"type":16,"description":11,"interventionNames":17},"short-term course prednisolone arm","EXPERIMENTAL",[18],"Drug: short-term course (12 week) glucocorticoid regimen",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Conventional 24-week glucocorticoid regimen","Weeks 1 - 4, Prednisolone 1mg\u002Fkg\u002Fday (max 80mg); Weeks 5 - 6: Prednisolone 0.8mg\u002Fkg\u002Fday (max 60mg); Weeks 7 - 8: Prednisolone 0.6mg\u002Fkg\u002Fday (max 50mg); Weeks 9 - 10: Prednisolone 0.5mg\u002Fkg\u002Fday (max 40mg); Weeks 11 - 12: Prednisolone 0.4mg\u002Fkg\u002Fday (max 30mg); Weeks 13 - 16: Prednisolone 0.3mg\u002Fkg\u002Fday (max 25mg); Weeks 17 - 20: Prednisolone 0.2mg\u002Fkg\u002Fday (max 15 Weeks 21 - 24: Prednisolone 0.1mg\u002Fkg\u002Fday (max 10mg).",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"short-term course (12 week) glucocorticoid regimen","Weeks 1 - 4, Prednisolone 1mg\u002Fkg\u002Fday (max 80mg); Weeks 5-8: Prednisolone 1mg\u002Fkg\u002Fday (max 80mg) on alternate days; 9-12: Prednisolone 0.5mg\u002Fkg\u002Fday (max 40mg) on alternate days",[15],[30],{"facility":31,"status":11,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"The First Affiliated Hospital of Wenzhou Medical University","Wenzhou","Zhejiang","325000","China","CN",{"type":38,"coordinates":39},"Point",[40,41],120.66682,27.99942,{"lat":41,"lon":40},[44],{"name":45,"role":46,"phone":47,"phoneExt":11,"email":48},"Tianxin Chen, PhD","CONTACT","+86057755578056","ctxzjf@163.com",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Tianxin Chen","Principal Investigator","100604587","phase-4-short-term-glucocorticoid-in-adult-steroid-sensitive-nephrotic-syndrome-the-coco-asteroid-study-100604587",false,"NCT07151456","Short-term gluCOCOrticoid in Adult STEROID-sensitive Nephrotic Syndrome: The COCO-ASTEROID Study","Short-term vs Conventional Glucocorticoid Therapy for the Treatment of the Initial Episode of Adult Patient With Steroid-sensitive Idiopathic Nephrotic Syndrome","Inclusion Criteria:\n\n* Urine protein: creatinine ratio ≥3000mg\u002Fg (300mg\u002Fmmol)\n* Serum\u002Fplasma albumin level \\\u003C 30g\u002FL\n* Age ≥ 16 years at the time of diagnosis\n* No prior therapy with steroids, immunosuppressive or cytotoxic agents for any form of renal disease (other than the 28 days of prednisolone therapy given initially as routine clinical practice)\n* No evidence of underlying systemic disorder or exposure to agents known to be associated with newly presenting steroid sensitive nephrotic syndrome\n* Informed consent\n* SSNS defined as Complete remission within 4 weeks of prednisone or prednisolone at standard dose\n\nExclusion Criteria:\n\n* Secondary nephrotic syndrome\n* Contradictions for glucocorticoids\n* SRNS: Lack of complete remission within 4 weeks of therapy with daily prednisone or prednisolone at standard dose\n* anti-PLA2R positive\n* Adults with histological changes other than minimal lesion or focal segmental glomerular sclerosis (FSGS) glomerulonephritis where renal biopsy has been undertaken\n* Adults with a prior history of poor compliance with medical therapy Known allergy to glucocorticoid therapy\n* Other situations where the researcher deems it inappropriate to participate in the study","ALL","16 Years",{"count":63,"type":64},224,"ESTIMATED","INTERVENTIONAL",[67],"PHASE4","This study will compare a short-term course (12 week) glucocorticoid regimen with the Conventional 24-week regimen as originally proposed by KDIGO. The purpose of the study is to determine a short-term course (12 week) of glucocorticoid decreases the time to first relapse in adults presenting with steroid sensitive nephrotic syndrome.",[70],"Idiopathic Nephrotic Syndrome","NOT_YET_RECRUITING","2025-08-25",{"date":74,"type":75},"2025-09-03","ACTUAL",{"date":77,"type":64},"2026-01",{"date":79,"type":64},"2029-12",{"name":5,"class":6},1]